

Steven F Dowdy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8656912/publications.pdf>

Version: 2024-02-01

31
papers

3,126
citations

430874

18
h-index

434195

31
g-index

32
all docs

32
docs citations

32
times ranked

4387
citing authors

#	ARTICLE	IF	CITATIONS
1	Protein Delivery by PTDs/CPPs. <i>Methods in Molecular Biology</i> , 2022, 2383, 257-264.	0.9	4
2	DNA/RNA heteroduplex oligonucleotides: An unanticipated twist in the delivery of ASOs. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 133-134.	5.1	2
3	RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients. <i>FASEB Journal</i> , 2021, 35, e21476.	0.5	6
4	Overcoming delivery barriers with LNPs. <i>Nature Materials</i> , 2021, 20, 575-577.	27.5	10
5	A Cdk4/6-dependent phosphorylation gradient regulates the early to late G1 phase transition. <i>Scientific Reports</i> , 2021, 11, 14736.	3.3	5
6	Targeting Plk1 with siRNAs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients. <i>Scientific Reports</i> , 2020, 10, 2688.	3.3	11
7	Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase. <i>Molecules</i> , 2019, 24, 3287.	3.8	14
8	Induction of RNAi Responses by Short Left-Handed Hairpin RNA Triggers. <i>Nucleic Acid Therapeutics</i> , 2017, 27, 260-271.	3.6	4
9	RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients. <i>Journal of Controlled Release</i> , 2017, 261, 199-206.	9.9	17
10	Enhanced generation of iPSCs from older adult human cells by a synthetic five-factor self-replicative RNA. <i>PLoS ONE</i> , 2017, 12, e0182018.	2.5	30
11	Enhancing Endosomal Escape for Intracellular Delivery of Macromolecular Biologic Therapeutics. <i>Scientific Reports</i> , 2016, 6, 32301.	3.3	250
12	Current views on inducing synthetic lethal RNAi responses in the treatment of cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 161-172.	3.1	12
13	Synthesis and Conjugation of Small Interfering Ribonucleic Neutral siRNAs. <i>Methods in Molecular Biology</i> , 2016, 1364, 1-9.	0.9	10
14	Efficient CRISPR-rAAV engineering of endogenous genes to study protein function by allele-specific RNAi. <i>Nucleic Acids Research</i> , 2015, 43, e45-e45.	14.5	26
15	Cationic PTD/CPP-mediated macromolecular delivery: charging into the cell. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1627-1636.	5.0	107
16	Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications. <i>Nature Biotechnology</i> , 2014, 32, 1256-1261.	17.5	165
17	Efficient Generation of Human iPSCs by a Synthetic Self-Replicative RNA. <i>Cell Stem Cell</i> , 2013, 13, 246-254.	11.1	253
18	Transdifferentiation of human fibroblasts into hepatocyte-like cells by defined transcriptional factors. <i>Hepatology International</i> , 2013, 7, 937-944.	4.2	22

#	ARTICLE	IF	CITATIONS
19	Protein transduction domain delivery of therapeutic macromolecules. <i>Current Opinion in Biotechnology</i> , 2011, 22, 888-893.	6.6	229
20	Efficient siRNA delivery by novel PTD-DRBD fusion proteins. <i>Cell Cycle</i> , 2010, 9, 424-425.	2.6	17
21	Whi5 Regulation by Site Specific CDK-Phosphorylation in <i>Saccharomyces cerevisiae</i> . <i>PLoS ONE</i> , 2009, 4, e4300.	2.5	61
22	Pathologic Prion Protein Infects Cells by Lipid-Raft Dependent Macropinocytosis. <i>PLoS ONE</i> , 2008, 3, e3314.	2.5	65
23	Influence of protein transduction domains on intracellular delivery of macromolecules. <i>Expert Opinion on Drug Delivery</i> , 2006, 3, 739-746.	5.0	96
24	Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. <i>Advanced Drug Delivery Reviews</i> , 2005, 57, 579-596.	13.7	397
25	Cationic TAT peptide transduction domain enters cells by macropinocytosis. <i>Journal of Controlled Release</i> , 2005, 102, 247-253.	9.9	598
26	Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids <i>in vivo</i> . <i>Expert Opinion on Drug Delivery</i> , 2005, 2, 43-51.	5.0	95
27	Protein Transduction Strategies for Target and Mechanism Validation. , 2004, , 91-118.		1
28	Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide. <i>PLoS Biology</i> , 2004, 2, e36.	5.6	177
29	Cell Penetrating Peptides in Drug Delivery. <i>Pharmaceutical Research</i> , 2004, 21, 389-393.	3.5	295
30	MEDICINE: Targeting Apoptotic Pathways in Cancer Cells. <i>Science</i> , 2004, 305, 1411-1413.	12.6	108
31	Anti-cancer protein transduction strategies: reconstitution of p27 tumor suppressor function. <i>Journal of Controlled Release</i> , 2003, 91, 45-51.	9.9	27